QLT Inc. company was founded in 1981 and is headquartered in Vancouver, Canada. QLT Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of pharmaceutical products, primarily in the field of ophthalmology. It offers Visudyne, a photosensitizer to treat the eye disease, known as wet age related macular degeneration; and also used for the treatment of subfoveal CNV due to pathologic myopia, or severe near-sightedness, and presumed ocular histoplasmosis or other macular diseases. The company also offers Eligard product line that includes one, three, four, and six month commercial formulations of Atrigel technology combined with leuprolide acetate for the treatment of prostate cancer. Its products in development include Visudyne therapy; punctal plug drug delivery system, an invasive drug delivery system for delivering various drugs topically to the eye through controlled sustained release to the tear film, under Phase II studies targeting the treatment of glaucoma and ocular hypertension; and QLT091001, a Phase Ia orally administered synthetic retinoid replacement therapy for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle, as well as OT-730, a prodrug of a beta adrenergic antagonist (a type of beta blocker) under investigation for the treatment of glaucoma.

GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins through transgenic animal technology. ATryn®, our recombinant form of human antithrombin, is the first transgenically produced protein to be approved anywhere in the world, having recently been approved by the European Commission for the prophylactic treatment of deep vein thrombosis in patients with hereditary antithrombin deficiencies that are undergoing surgical procedures. ATryn® is produced in the milk of goats developed using micro-injection technology to incorporate a human antithrombin transgene. In addition to ATryn®, GTC is developing additional recombinant forms of therapeutic proteins normally found in human blood plasma as well as monoclonal antibodies. These products have potential applications in hematology, oncology, and autoimmune diseases.

Cytokinetics, Incorporated company was founded in 1997 and is headquartered in South San Francisco, California. Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule drug therapeutics for the treatment of cardiovascular diseases and cancer. The company’s lead product includes CK-1827452, a cardiac muscle myosin activator, which is in Phase IIa clinical trials for the treatment of heart failure. Its products under development stage comprise Ispinesib, a kinesin spindle protein inhibitor that is in Phase I/II clinical trials for the treatment of metastatic breast cancer; SB-743921, which is in Phase I/II trials to treat patients with non-Hodgkin or Hodgkin lymphoma; and GSK-923295, centromere-associated protein E inhibitor, which is in Phase I clinical trials to treat patients with refractory solid tumors. The company’s products under preclinical stage consist of CK-2017357, a skeletal sarcomere activator for the treatment of diseases and conditions associated with muscle weakness or wasting; and smooth muscle myosin inhibitor for the treatment of pulmonary arterial hypertension, and diseases and medical conditions associated with bronchoconstriction. It has a strategic alliance with Amgen Inc. to discover, develop, and commercialize novel small-molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure, as well as with GlaxoSmithKline to develop GSK-923295.

Tetracore, Inc. company's FDA-approved Redline lab test can distinguish anthrax bacteria from similar microorganisms. Other bioterrorism countermeasures the firm offers include the BioThreat Alert testing kit used by first responders to detect various biological toxins including botulinum toxin (botulism) and staphylococcus aureus enterotoxin B (SEB). Tetracore also sells veterinary diagnostic (VetAlert) tests for foot-and-mouth disease, West Nile, and other diseases, and it markets antibodies (proteins) for use by research labs.

Dragon Pharmaceutical is looking to build a pharmaceutical empire in the PRC. Headquartered in Canada, the company has production facilities within mainland China that manufacture active pharmaceutical ingredients (APIs), intermediates, and finished formulations. It sells its bulk APIs and intermediates, which are used in antibiotic formulations, both in China and internationally (mainly in India). Its finished products (sold only in China) are primarily injectable cephalosporin antibiotics. In 2007 Dragon Pharmaceutical divested its biotech division in order to focus on its core antibiotic operations. CEO Yanlin Han holds nearly half of the company's stock and is seeking to buy the balance.

CPEX Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, licensing, and commercialization of pharmaceutical products utilizing its validated drug delivery technology. Its drug delivery technology, CPE-215 technology, enhances permeation and absorption of pharmaceutical molecules across biological membranes such as the skin, nasal mucosa and eye. The company's principal product Testim, a gel for testosterone replacement therapy is licensed to Auxilium Pharmaceuticals, Inc. that markets the product in the United States, Europe, and other countries. It also holds U.S. and international patents, and other proprietary rights to technologies that facilitate the absorption of drugs. In addition, CPEX Pharmaceuticals, Inc. is developing an intranasal insulin product candidate, Nasulin, which is in Phase II clinical trials. The company was incorporated in 2007 and is headquartered in Exeter, New Hampshire.

Vivalis SA was founded in 1999 and is headquartered in Saint-Herblain, France. Vivalis SA, a biopharmaceutical company, develops and sells cell-based solutions to the pharmaceutical industry for the manufacture of viral vaccines and therapeutic proteins. Its proprietary technologies include EB66 cell line platform, which is derived from duck embryonic stem cells that presents industrial and regulatory characteristics to replace the eggs in the production of vaccines and to produce antibodies with enhanced antibody dependent cell cytotoxicity activity; and the 3D-SCREEN molecular screening platform that is used to identify and develop molecules for the purpose of blocking the action of proteins involved in major viral pathologies. The company also develops drugs for the prevention and treatment of viral diseases, notably for the treatment of hepatitis C.

Applied Molecular Evolution (AME) is part of the Lilly Biotechnology Center of San Diego. AME is a leader in applying directed molecular evolution to improve healthcare by discovering, optimizing and developing human biotherapeutics. Since its inception, AME’s principal focus has been on applying its proprietary AMEsystem™ technology platform to the full range of protein therapeutic candidates including antibodies, cytokines, hormones and enzymes to develop novel human biotherapeutic candidates.Since February 2004, AME has been a wholly-owned subsidiary of Eli Lilly and Company and is an integral part of Lilly’s research organization. Lilly, a leading innovation-driven corporation is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Lilly provides answers – through medicines and information – for some of the world’s most urgent medical needs.

Laboratoires Arkopharma's products offer a glimpse of modern worries: ampoules of fat reducers, tablets to help quit smoking, creams to tackle cellulite, and capsules to alleviate anxiety and stress. Arkopharma produces plant-derived OTC drugs and nutritional supplements. The company also manufactures homeopathic remedies and cosmetics. Arkopharma markets its products under a variety of brands, including Arkocaps, Arkofluide, 4.3.2.1. Slim, Phyto Soya, and Plante System. Subsidiaries of the company can be found in Australia, Europe, and the UK. The founding Rombi family controls the company through its holding company Imarko.

Helicon Therapeutics is a development-stage biotechnology firm working on new therapies for memory loss and other cognition disorders. The company's research and development efforts focus on a protein that controls the signal pathway key to forming long-term memories. Scientists working for Helicon Therapeutics discovered the protein while studying the fruit fly genome. The company is working on drugs to not only maintain memory but also possibly to prevent memories from forming in the first place. Lead drug candidate HT-0712 has shown the ability to improve long-term memory in rats. Other candidates are in early stages of development.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.